Literature DB >> 9343231

Late gene expression from the Epstein-Barr virus BcLF1 and BFRF3 promoters does not require DNA replication in cis.

T R Serio1, J L Kolman, G Miller.   

Abstract

Late gene expression follows and is dependent upon lytic replication of the viral genome. Although experimental evidence is lacking, lytic viral DNA replication is believed to remove modifications or binding factors from the genome which serve to repress late gene expression during latency or the early lytic cycle. We have developed a reporter assay to begin characterizing the mechanisms that regulate late gene expression in Epstein-Barr virus (EBV). In this model system, the activities of late promoter-reporter fusions are measured following transient transfection into tissue culture cells expressing EBV during different stages of the lytic cycle. This system faithfully recapitulates late expression patterns from the endogenous virus, implicating specific cis-active sequences in the control of late gene expression. In addition, these promoters respond only indirectly to the viral immediate-early transactivator, ZEBRA. This indirect response is mediated by other viral or virally induced activities downstream of ZEBRA in the lytic cascade. In this system, late gene expression is sensitive to inhibitors of the viral DNA polymerase such as phosphonoacetic acid, although the reporters lack a eukaryotic origin of replication and are not replicated under the assay conditions. Thus, replication of the transcriptional template is not a prerequisite for expression with late kinetics, a finding inconsistent with the current models which posit a cis-active relationship between lytic EBV DNA replication and late gene expression. Rather, analysis of this system has revealed a trans relationship between late gene expression and viral DNA replication and highlights the indirect and complex link between these two events.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9343231      PMCID: PMC192337     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Inhibition by phosphonoacetate of the in vitro outgrowth of Epstein-Barr virus genome-containing cell lines from the blood of infectious mononucleosis patients.

Authors:  A B Rickinson; S Finerty; M A Epstein
Journal:  IARC Sci Publ       Date:  1978

2.  Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma.

Authors:  J Menezes; W Leibold; G Klein; G Clements
Journal:  Biomedicine       Date:  1975-07

3.  Inhibition of Epstein-Barr virus DNA synthesis and late gene expression by phosphonoacetic acid.

Authors:  W C Summers; G Klein
Journal:  J Virol       Date:  1976-04       Impact factor: 5.103

4.  Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA.

Authors:  J Countryman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

5.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

6.  Mechanism of inhibition of Epstein-Barr virus replication by phosphonoformic acid.

Authors:  A K Datta; R E Hood
Journal:  Virology       Date:  1981-10-15       Impact factor: 3.616

7.  Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies.

Authors:  G R Pearson; B Vroman; B Chase; T Sculley; M Hummel; E Kieff
Journal:  J Virol       Date:  1983-07       Impact factor: 5.103

8.  Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells.

Authors:  J L Yates; N Warren; B Sugden
Journal:  Nature       Date:  1985 Feb 28-Mar 6       Impact factor: 49.962

9.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

10.  Identification of a rare Epstein-Barr virus variant that enhances early antigen expression in Raji cells.

Authors:  M Rabson; L Heston; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

View more
  30 in total

1.  The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.

Authors:  R Feederle; M Kost; M Baumann; A Janz; E Drouet; W Hammerschmidt; H J Delecluse
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

2.  Autostimulation of the Epstein-Barr virus BRLF1 promoter is mediated through consensus Sp1 and Sp3 binding sites.

Authors:  T Ragoczy; G Miller
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  The Epstein-Barr virus BcRF1 gene product is a TBP-like protein with an essential role in late gene expression.

Authors:  Henri Gruffat; Faouzi Kadjouf; Bernard Mariamé; Evelyne Manet
Journal:  J Virol       Date:  2012-03-28       Impact factor: 5.103

4.  Lytic cycle gene regulation of Epstein-Barr virus.

Authors:  Wolfgang Amon; Ulrich K Binné; Helen Bryant; Peter J Jenkins; Claudio Elgueta Karstegl; Paul J Farrell
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  Phosphoacceptor site S173 in the regulatory domain of Epstein-Barr Virus ZEBRA protein is required for lytic DNA replication but not for activation of viral early genes.

Authors:  Ayman El-Guindy; Lee Heston; Henri-Jacques Delecluse; George Miller
Journal:  J Virol       Date:  2007-01-10       Impact factor: 5.103

6.  De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.

Authors:  Jianjiang Ye; Lyndle Gradoville; Derek Daigle; George Miller
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

7.  Binding of RBP-Jkappa (CSL) protein to the promoter of the Kaposi's sarcoma-associated herpesvirus ORF47 (gL) gene is a critical but not sufficient determinant of transactivation by ORF50 protein.

Authors:  Pey-Jium Chang; Joseph Boonsiri; Shih-Shan Wang; Li-Yu Chen; George Miller
Journal:  Virology       Date:  2009-12-16       Impact factor: 3.616

8.  The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes.

Authors:  T Ragoczy; L Heston; G Miller
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

9.  A functionally distinct TATA box required for late progression through the Epstein-Barr virus life cycle.

Authors:  T R Serio; N Cahill; M E Prout; G Miller
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

Review 10.  An Epigenetic Journey: Epstein-Barr Virus Transcribes Chromatinized and Subsequently Unchromatinized Templates during Its Lytic Cycle.

Authors:  Adityarup Chakravorty; Bill Sugden; Eric C Johannsen
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.